Sign Up

MIG Capital leads CHF 7.75 million seed financing for ASTRA Therapeutics

MIG Capital, through its MIG Fonds, is investing 3 million Swiss Francs (CHF) in the Swiss start-up which designs precision drugs against eukaryotic pathogens.

Digitalis Ventures co-leads the round with additional investment from Borealis Ventures, Kickfund and Venture Kick.

Eukaryotic pathogens cause illness and death in animals, humans, and crops.

MUNICH, Germany, and VILLIGEN, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- MIG Capital AG, one of Germany's leading venture capital firms, announced today that it is heading a seed financing of CHF 7.75 million for ASTRA Therapeutics with U.S. venture capital firm Digitalis Ventures as co-lead and Borealis Ventures, Kickfund and Venture Kick also participating in the round. MIG Fonds 17 and 18 have allocated CHF 3 million for the Swiss start-up, based at the Park InnovAARE innovation campus in Villigen, Switzerland.

Founded in 2022, ASTRA Therapeutics AG designs and develops novel parasitic agents (parasiticides) that control parasites by inhibiting cell division in parasites while sparing hosts. The company generates species-specific drug leads targeting tubulin, known as Parabulins®, through its proprietary drug development platform ParaX®.

Parabulins® are novel drugs (New Molecular Entities, NME) targeting important indications in the veterinary market. ASTRA's pipeline includes over 15 patentable chemical classes featuring nanomolar-potent candidates for common parasites such as coccidia in farm animals and heartworm in dogs and cats. Initial in vivo proof of concept for multiple NMEs has been demonstrated.

Natacha Gaillard, PhD, Founder and Co-CEO of ASTRA Therapeutics, said: "The animal health market is facing an ever-increasing need for novel anti-parasite drugs to combat the growing threat of drug resistance, ensure the health ...